Statistics on Biotechnology Use  
Results by fields of operation
Business Sector Biotechnology indicators by company size.
Unidades: specified in variables

;Fewer than 250 employees;250 or more employees;Total 2021;
No. of companies carrying out R&D in Biotechnology;1.155;145;1.299;
%Companies according to biotechnology used: Genetic code;29,7;39,5;30,8;
%Companies according to biotechnology used: Functional units;37,4;46,5;38,4;
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;20,1;33,3;21,5;
%Companies according to biotechnology used: Bioprocesses;49,2;63,2;50,8;
%Companies according to biotechnology used: Sub-cellular organisms;7,5;15,9;8,5;
%Companies according to biotechnology used: Bio-computing;23,7;26,4;24;
%Companies according to biotechnology used: Nanobiotechnology;12,2;11,1;12,1;
%Companies according to biotechnology used: Other;17,2;14,6;16,9;
Companies in which biotechnology activities are: Main and/or exclusive;544;15;559;
Companies in which biotechnology activities are: A secondary line of business;191;39;230;
Companies in which biotechnology activities are: A tool necessary for production;420;90;510;
%Company by field(s) of ultimate application of biotechnology use: Human Health;45,9;42,3;45,5;
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;15,9;12,5;15,5;
%Company by field(s) of ultimate application of biotechnology use: Food products;31,9;35,5;32,3;
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;24,1;20,8;23,8;
%Company by field(s) of ultimate application of biotechnology use: Environment;16;12,5;15,6;
%Company by field(s) of ultimate application of biotechnology use: Industry;13,9;12,5;13,7;
Personnel in R&D in biotechnology (no. of persons);9.560;6.190;15.750;
Personnel in R&D in biotechnology (no. of persons): Research personnel;5.506;2.874;8.379;
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;4.055;3.316;7.371;
Personnel in R&D in biotechnology (no. of persons). Women;4.963;3.748;8.711;
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;2.838;1.673;4.510;
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;2.125;2.075;4.200;
Personnel in R&D in biotechnology (FTE);6.711;4.817,6;11.528,6;
Personnel in R&D in biotechnology (FTE): Research personnel;4.162,2;2.180,5;6.342,7;
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;2.548,8;2.637,1;5.185,9;
Personnel in R&D in biotechnology (FTE). Women;3.575,2;2.964,6;6.539,7;
Personnel in R&D in biotechnology (FTE). Women: Research personnel;2.167,4;1.288,4;3.455,7;
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;1.407,8;1.676,2;3.084;
Internal expenditure on R&D (thousands of euros);593.445;445.137;1.038.582;
1) By nature of the expense: Current expenses;531.987;408.103;940.091;
1.1) Remuneration to research personnel;194.798;126.772;321.570;
1.2) Remuneration to technical and auxiliary personnel;91.565;103.271;194.836;
1.3) Other current expenses;245.624;178.061;423.685;
2) By nature of the expense: Capital expenses;61.458;37.033;98.492;
2.1) Land and buildings;7.788;2.411;10.199;
2.2) Equipment and instruments;40.235;32.349;72.584;
2.3) Acquisition of specific R&D software;3.600;2.121;5.721;
2.4) Otros productos de propiedad intelectual específicos para I+D;9.835;152;9.987;
1.1) By origin of the funds: Own funds;403.266;308.222;711.488;
1.2) By origin of the funds: From companies;75.949;45.789;121.738;
1.3) By origin of the funds: Public Administration funds;76.924;30.552;107.477;
1.4) By origin of the funds: From Universities;192;0;192;
1.5) By origin of the funds: From non profit private institutions;1.543;9.213;10.756;
1.6) By origin of the funds: Foreign funds;35.570;51.360;86.931;
Purchase of R&D services in biotechnology (thousands of euros);75.599;69.958;145.557;
Purchase of R&D services in biotechnology (thousands of euros): In Spain;53.934;41.981;95.915;
Purchase of R&D services in biotechnology (thousands of euros): Abroad;21.665;27.977;49.642;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;42,3;23,7;40,2;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;13,1;13,9;13,2;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;19,4;16;19;
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;11;15,3;11,5;
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;16,5;10,4;15,9;
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;17,8;10,4;17;
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;16,1;19,5;16,4;
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;41,2;34,8;40,5;
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;56,1;46,5;55;
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;22,3;18,7;21,9;
% Companies with income of an international origin related to biotechnological activities;24,2;18,1;23,5;
% Turnover representing income of an international origin related to biotechnological activities;10,6;0,8;1,9;
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;56;69,8;61,6;
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;44;30,2;38,4;
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;93,8;78,7;87,6;
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;4,9;19,6;10,9;
% Income of an international origin related with activities according to the classification: Operating source abroad;0,6;1,8;1,1;
% Income of an international origin related with activities according to the classification: Other;0,6;0;0,4;
Notas:
'.'=numeric piece of data equal to zero not resulting from rounding 

 FTE: Full Time Equivalent
Fuente: National Statistics Institute